IRWD

Ironwood Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

0.880

+0.075(9.317%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.140

Open

0.920

VWAP

1.01

Vol

5.26M

Mkt Cap

142.40M

Low

0.870

Amount

5.29M

EV/EBITDA(TTM)

8.01

Total Shares

158.96M

605.94M

EV/OCF(TTM)

7.72

P/S(TTM)

0.41

Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q1

85.50M

-5.57%

0.095

+375%

82.60M

-9.82%

-0.030

+50%

Estimates Revision

The market is revising No Change the revenue expectations for Ironwood Pharmaceuticals, Inc. (IRWD) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 11.11%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+11.11%

In Past 3 Month

3 Analyst Rating

13.64% Upside

Wall Street analysts forecast IRWD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRWD is 1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

3 Hold

0 Sell

Hold

13.64% Upside

Current: 0.880

Low

1.00

Averages

1.00

High

1.00

13.64% Upside

Current: 0.880

Low

1.00

Averages

1.00

High

1.00

Jefferies

Amy Li

Strong Buy

Hold

Downgrades

$8 → $0.7

2025-04-15

Reason

Jefferies

Amy Li

Price Target

$8 → $0.7

2025-04-15

Downgrades

Strong Buy

Hold

Reason

Jefferies analyst Amy Li downgraded Ironwood to Hold from Buy with a price target of 70c, down from $8, after the FDA said the company will likely need another confirmatory Phase 3 trial for apraglutide. The firm cites the regulatory setback for the downgrade and wants more clarity on the path forward before recommending the shares.

Wells Fargo

Mohit Bansal

Buy

Hold

Downgrades

$7 → $1

2025-04-15

Reason

Wells Fargo

Mohit Bansal

Price Target

$7 → $1

2025-04-15

Downgrades

Buy

Hold

Reason

Wells Fargo downgraded Ironwood to Equal Weight from Overweight with a price target of $1, down from $7.

Leerink Partners

Faisal Khurshid

Hold

Maintains

$3 → $1

2025-04-14

Reason

Leerink Partners

Faisal Khurshid

Price Target

$3 → $1

2025-04-14

Maintains

Hold

Reason

Leerink analyst Faisal Khurshid lowered the firm's price target on Ironwood to $1 from $3 and keeps a Market Perform rating on the shares after the company announced they will need to run an additional confirmatory Phase 3 trial for apraglutide in short bowel syndrome in order to seek FDA approval. Apraglutide was meant to be the next leg of the story following Linzess' loss of exclusivity and today's development adds to the company's financial uncertainty, making it "a painful development," the analyst tells investors.

JMP Securities

Roy Buchanan

Buy

Maintains

$23 → $14

2025-01-30

Reason

JMP Securities

Roy Buchanan

Price Target

$23 → $14

2025-01-30

Maintains

Buy

Reason

JMP Securities analyst Jason Butler lowered the firm's price target on Ironwood to $14 from $23 and keeps an Outperform rating on the shares. Ironwood's corporate restructuring acknowledges continued headwinds for LINZESS but prioritizes apraglutide, which the firm continues to view as the long-term value driver, the analyst tells investors in a research note. The announcement that long-term extension data will now be included in the new drug application submission is a clear demonstration of management's focus on maximizing the asset's commercial potential, JMP says.

Craig-Hallum

Chase Knickerbocker

Strong Buy

Maintains

$10 → $8

2025-01-22

Reason

Craig-Hallum

Chase Knickerbocker

Price Target

$10 → $8

2025-01-22

Maintains

Strong Buy

Reason

Leerink Partners

Faisal Khurshid

Hold

Initiates

2024-09-09

Reason

Leerink Partners

Faisal Khurshid

Price Target

2024-09-09

Initiates

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Ironwood Pharmaceuticals Inc (IRWD.O) is 2.55, compared to its 5-year average forward P/E of 14.73. For a more detailed relative valuation and DCF analysis to assess Ironwood Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

14.73

Current PE

2.55

Overvalued PE

35.77

Undervalued PE

-6.31

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

10.20

Current EV/EBITDA

5.49

Overvalued EV/EBITDA

16.51

Undervalued EV/EBITDA

3.89

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Undervalued

5Y Average PS

3.54

Current PS

0.44

Overvalued PS

4.92

Undervalued PS

2.16

Financials

Annual

Quarterly

FY2025Q1

YoY :

-45.05%

41.14M

Total Revenue

FY2025Q1

YoY :

-192.07%

-10.55M

Operating Profit

FY2025Q1

YoY :

+798.27%

-37.39M

Net Income after Tax

FY2025Q1

YoY :

+666.67%

-0.23

EPS - Diluted

FY2025Q1

YoY :

-55.64%

19.92M

Free Cash Flow

FY2025Q1

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q1

YoY :

-111.62%

24.68

FCF Margin - %

FY2025Q1

YoY :

+1534.35%

-90.87

Net Margin - %

FY2025Q1

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 854.31% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

428.3K

USD

0-12

Months

44.9K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

2.3M

Volume

Months

6-9

2.0M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areSelling! The selling amount has increased 854.31% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

428.3K

USD

0-12

Months

44.9K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

IRWD News & Events

Events Timeline

2025-05-07 (ET)

2025-05-07

07:39:11

Ironwood affirms FY25 revenue $260M-$290M, consensus $286.8M

2025-05-07

07:38:15

Ironwood reports Q1 EPS (14c), two estimates (3c)

2025-04-25 (ET)

2025-04-25

07:21:41

Ironwood backs FY25 revenue view $260M-$290M, consensus $287.07M

News

7.0

04-25Newsfilter

Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance

1.0

04-22Newsfilter

Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support

4.0

04-15Benzinga

This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday